CBD has lower affinity for CB receptors. It acts being an antagonist or partial antagonist at endogenous cannabinoid receptors (both equally CB1 and CB2 receptor kinds along with other G-protein-coupled receptors [GPCRs]) by inhibiting whole binding of immediate ligands, and will act mostly at a